The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.
Amsterdam, The Netherlands – Monday 2 September 2013 – The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study. The lack of efficacy of RVX-208 is “disappointing and surprising, given promising earlier findings,” noted lead investigator Stephen Nicholls MBBS, PhD, Deputy Director at the South Australian Health and Medical Research Institute, Professor of Cardiology at the University of Adelaide and Consultant Cardiologist at the Royal Adelaide Hospital in Adelaide, Australia. However, the failure of RVX-208 to incrementally impact atherosclerotic plaque should not be interpreted as a failure of the hypothesis that increasing the level and activity of HDL could result in this benefit, he said.
“RVX-208 represents the first epigenetic foray into the metabolic treatment of cardiovascular disease, and ongoing clinical trials will evaluate the potential cardiovascular efficacy of other agents that target HDL.”
ASSURE was a prospective, randomized, double-blind clinical trial carried out at 60 centers.It randomized 323 patients with low HDL and coronary disease who had a target blood vessel for imaging with less than 50% stenosis.All patients received treatment with either atorvastatin 10-40 mg daily or rosuvastatin 5-20 mg daily during the study and were also randomized to receive either RVX-208 100 mg (n=244) or placebo (n=80) twice daily for 26 weeks.The primary and secondary outcomes of the study were change from baseline in percent atheroma volume (PAV) and normalized total atheroma (TAV), both measures of the amount of plaque present in the coronary artery.Intravascular ultrasonography was used at baseline and the end of the study to measure these outcomes.Of the 281 patients that remained in the study and had this imaging, while a trend towards plaque regression was observed with RVX-208 compared with baseline, there was no significant difference in efficacy outcomes between the groups, said Dr. Nicholls.However, there were more discontinuations due to adverse events in the RVX-280 group (3.7% vs. 2.5%) as well as significantly more elevations of liver enzymes at triple the normal limit or more (7.0% vs. 0%, P=0.009). In terms of efficacy, PAV decreased by 0.40% in the RVX-208 group compared to 0.30% in the placebo group ( P=0.81) and TAV decreased by 4.2 mm3 vs 3.8 mm3 respectively (P=0.86). HDL cholesterol increased by 10.9% in the RVX-280 group compared to 7.7% in the placebo group (P=0.32), and LDL cholesterol decreased by 16.0% vs 17.6% with placebo (P=0.72).There were differences in cardiovascular events between the groups (7.4% in the RVX-208 group vs 13.8% in the placebo; P=0.09), and all liver enzyme elevations occurred within the first 2 months of treatment with spontaneous y when the study drug was discontinued. Additionally, the impact of RVX-208 on apoA1 levels from baseline was not significantly different from placebo (P=0.18). The levels increased by 10.6% (P<0.001 compared with baseline) in the placebo group and 12.8% (P<0.001 compared with baseline) in the RVX-208 group.
“We anticipated that RVX-208 might promote regression of atherosclerotic plaque, however it did not demonstrate this benefit,” said Dr. Nicholls. “This is an intriguing therapeutic agent from a small company, and many in the HDL field found it exciting. The preliminary data made them wonder if it would be as good as infusional HDL agents and they elected to test this in a highly provocative fashion, over only 6 months. That is quite a change from the traditional studies of oral agents, which typically take 18-24 months,” he explained.
ASSURE’s lack of positive findings suggests that oral therapies may need longer to show an effect, he added. “We can't make any extrapolations about what might happen with the drug over a longer period because we did not test this, but if you look at longer trials of established therapies, there is a suggestion that, while there may be some early impact on plaque, significant change does not occur quickly and appears take a longer period of time.”He suggested the negative finding might either reflect lack of efficacy of RVX-208 “or the inability to improve on benefits produced by statins and other background therapies in the study”.
“In the quarter century following the introduction of statins to clinical practice there has been an intensive, yet unsuccessful, search to identify new strategies to achieve greater cardiovascular risk reductions,” he added. “The search to identify a strategy that promotes HDL functionality, and improve cardiovascular outcomes continues.”
DISCLOSURES:S.J.N. reports receiving research support from AstraZeneca, Novartis, Eli Lilly, Anthera, LipoScience, Roche and Resverlogix and has received honoraria or been a consultant for AstraZeneca, Roche, Esperion, Abbott, Pfizer, Merck, Takeda, LipoScience, Omthera, Novo-Nordisk, Sanofi-Aventis, Atheronova, Anthera, CSL Behring and Boehringer. H.B.B. is a consultant for Merck, AstraZeneca, Eli Lilly, Roche, Amgen and Sanofi. C.M.B. has received research support from Abbott, Amarin, Amgen, Eli Lilly, GlaxoSmithKline, Genentech, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo, Takeda, National Institutes of Health and American Heart Association, is a consultant for Abbott, Aegerion, Amarin, Amgen, Arena, Cerenis, Esperion, Genentech, Genzyme, Kowa, Merck, Novartis, Omthera, Pfizer, Resverlogix, Regeneron, Roche and Sanofi-Synthelabo and serves on the speaker’s bureau for Abbott. P.J.B. has received research grants from Merck and Pfizer, received honoraria from Amgen, AstraZeneca, ISIS, Kowa, Merck, Novartis, Pfizer and Roche and serves on advisory boards for AstraZeneca, CSL Behring, Kowa, Eli Lilly, Merck, Novartis, Pfizer and Roche. J.J.P.K. has received research support from the Dutch Heart Foundation (2010T082) and has received honoraria or has been a consultant for AstraZeneca, Novartis, Eli Lilly, Anthera, Roche, Resverlogix, Pfizer, Merck, Omthera, Sanofi-Aventis, Regeneron, Amgen, AtheroNova, CSL Behring, Boehringer Ingelheim, Aegerion, the Medicines Company, Isis Pharmaceuticals, Genzyme, Amarin, Xenon Pharma, Servier and Cerenis. S.E.N. has received research support from AstraZeneca, Eli Lilly, Pfizer, Takeda, Sankyo, and Sanofi-Aventis. He has consulted for a number of pharmaceutical companies without financial compensation. All honoraria, consulting fees or any other payments from any for-profit entity are paid directly to charity, so that neither income nor any tax deduction is received. No assistance in the preparation of this article is to be declared. R.P., K.U., Y.K., M.B. and K.W. have no potential conflicts to disclose. A.G., J.J. and N.W. are employees of Resverlogix Corporation and are thus eligible for Resverlogix stock and stock options.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2013. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.More information on the ESC Press Conference page: Hot Line III: Late Breaking Trials on Risk factors and Diabetes
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2013The ESC Congress is currently the world’s premier conference on the science, management and prevention of cardiovascular disease. The spotlight of this year's event is "The Heart Interacting with Systemic Organs". ESC Congress 2013 takes place from 31 August to 4 September at the RAI centre in Amsterdam, Netherlands. More information on ESC Congress 2013 contact the ESC Press Office.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved